| scholarly article | Q13442814 |
| P2093 | author name string | M Kai | |
| M Ferrari | |||
| M Milosevic | |||
| A Holder | |||
| K Yokoi | |||
| Y T Liu | |||
| A Ziemys | |||
| M Kojic | |||
| V Simic | |||
| P2860 | cites work | A New Imaging Platform for Visualizing Biological Effects of Non-Invasive Radiofrequency Electric-Field Cancer Hyperthermia | Q27321706 |
| Drug penetration in solid tumours | Q29614404 | ||
| Nanoparticle therapeutics: an emerging treatment modality for cancer | Q29615628 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review | Q29617388 | ||
| Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers | Q33235069 | ||
| Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment | Q34052540 | ||
| Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer | Q34546077 | ||
| Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. | Q34589774 | ||
| Delivering nanomedicine to solid tumors | Q34726981 | ||
| Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies | Q35124674 | ||
| Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue | Q35754443 | ||
| Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier. | Q36217918 | ||
| Lessons from phase III clinical trials on anti-VEGF therapy for cancer | Q36366446 | ||
| Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases | Q36471409 | ||
| Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. | Q37712444 | ||
| Treating metastatic cancer with nanotechnology | Q37970910 | ||
| Pharmacokinetic studies in cancer chemotherapy: Usefulness in clinical practice | Q41558088 | ||
| Computational analysis of drug transport in tumor microenvironment as a critical compartment for nanotherapeutic pharmacokinetics | Q41762577 | ||
| Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan | Q43675453 | ||
| Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics | Q45146022 | ||
| A composite smeared finite element for mass transport in capillary systems and biological tissue | Q47288082 | ||
| Functional precision cancer medicine-moving beyond pure genomics | Q48013156 | ||
| Tumor progression effects on drug vector access to tumor-associated capillary bed. | Q50205781 | ||
| Association of intratumoral pharmacokinetics of fluorouracil with clinical response | Q72676647 | ||
| Extravascular diffusion in normal and neoplastic tissues | Q72719918 | ||
| The role of payload hydrophobicity in nanotherapeutic pharmacokinetics | Q87821698 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heterogeneity | Q928498 |
| P304 | page(s) | 99-105 | |
| P577 | publication date | 2018-10-14 | |
| P1433 | published in | Journal of Controlled Release | Q6295046 |
| P1476 | title | Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance | |
| P478 | volume | 291 |
| Q92807535 | An approach for vascular tumor growth based on a hybrid embedded/homogenized treatment of the vasculature within a multiphase porous medium model |
| Q89547961 | Extension of a multiphase tumour growth model to study nanoparticle delivery to solid tumours |
| Q89638584 | Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment |
| Q92955340 | Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy |
Search more.